摘要
目的观察并分析非霍奇金淋巴瘤患者治疗前及经利妥昔单抗联合化疗治疗后6个月外周血淋巴细胞亚群的动态变化。方法应用流式细胞术分别检测健康志愿者40例、初治患者26例及经利妥昔单抗联合化疗患者16例6个月后外周血T淋巴细胞亚群、B淋巴细胞亚群及自然杀伤(NK)细胞的比例。结果与正常对照组比较,非霍奇金淋巴瘤患者化疗前外周血中CD3+、CD4+、CD8+、CD4+/CD8+淋巴细胞亚群计数无统计学差异(P>0.05),CD19+淋巴细胞明显降低,而NK细胞则高于正常对照组(P<0.05);利妥昔单抗联合化疗后CD19+淋巴细胞较治疗前明显降低(P<0.05),而T淋巴细胞亚群及NK细胞计数无统计学差异(P>0.05)。结论利妥昔单抗联合化疗能够迅速有效地抑制B淋巴细胞淋巴瘤的恶性克隆增殖,在短期内,对机体T淋巴细胞及NK细胞的影响不大,本组病例随访时间仅6个月,有待于继续观察随访。
Objective To observe and anyalyze the peripheral blood lymphocyte subsets in non-Hodgkin′s lymphoma patients with the regimen of rituximab combined chemotherapy after 6 months.Methods Application of flow cytometry was used to detect the peripheral blood T lymphocyte subsets,B lymphocyte subsets and natural killer（NK） cell ratio in 40 cases of healthy volunteers,26 cases of patients untreated,and 16 patients treated for 6 months with rituximab combined chemotherapy.Results Compared with the normal control group,the peripheral blood CD3＋,CD4＋,CD8＋,CD4＋/CD8＋lymphocyte count of non-Hodgkin′s lymphoma patients before chemotherapy,was no significant difference（P0.05）,CD19＋lymphocytes decreased significantly and NK cells increased（P0.05）.After rituximab combined chemotherapy,CD19＋ lymphocytes was significantly lower than that before the treatment（P0.05）,and T lymphocyte subsets and NK cells was no significant difference（P0.05）.Conclusion Rituximab combined chemotherapy can quickly and effectively inhibit the malignant B cell lymphoma clone proliferation.There was little effect on T lymphocytes and NK cells in a short time.The follow-up period of this study was only 6 months,and further observation is needed.
出处
《医学综述》
2011年第19期3018-3020,共3页
Medical Recapitulate
